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characterize the relationship between immunophenotypic markers
of T cell maturation and functional attributes of T cells, we
optimized an 8-color, 10-parameter cytokine ﬂow cytometry
(CFC) approach and examined PBMC in 3 healthy donors. PBMC
were exposed to stimuli that both bypass and signal through the T
cell receptor (PMA/Ionomycin&em;P:I and staph enterotoxin
B&em;SEB, respectively) and stained with CD45RA and CD27 to
demarcate naı¨ve (N, CD45RACD27), memory (M, CD45RA-
CD27-) and late-memory (LM, CD45RACD27-) CD4 and
CD8 T cells. We assessed the production of effector cytokines
(IL-2, IFN, TNF
 and MIP1) within the three maturation
subsets. Following PMA and SEB stimulation, all maturation sub-
sets (N, M and LM) of CD4 and CD8 T cells produced IFN.
TNF
 production was similarly distributed after P:I stimulation.
However, after SEB stimulation, LM CD4 and CD8 cells
produced only 2.5% and 8.5% of total TNF
, respectively. Pro-
duction of IL-2 and MIP1- was much more skewed, with LM
cells contributing little to total IL-2 production after stimulation
with P:I (0.2% of total, CD4; 0%, CD8) or SEB (CD4, 2.1%;
CD8, 2.8%). While LM cells produced little or no IL-2, they
produced the bulk of MIP1- following stimulation with P:I
(96.5%, CD4; 84.8%, CD8) or SEB (97.5%, CD4; 70.7%, CD8).
Co-production of IL-2 and IFN in T cells has recently been
postulated to be important for protective immunity. Importantly,
no IL-2IFN cells were seen in the LM compartment follow-
ing P:I stimulation (CD4 Distribution: 8.9% N, 91.1% M, 0%
LM; CD8: 15.7% N, 84.3% M, 0% LM). Results following SEB
stimulation were similar (CD4: 3.3% N, 94.9% M, 1.8% LM;
CD8: 12.2% N, 87.8% M, 0% LM). Overall, these results suggest
that: 1) T cell maturation stage does correlate strongly with func-
tional capacity; 2) Nearly all IL-2 production occurs in N and M
cells; 3) LM cells produce little or no IL-2; but most of total
MIP-1; 4) IL-2/IFN co-production is absent in LM cells, per-
haps suggesting why late-stage skewing after SCT is associated
with functional T cell impairment; and 5) Maturation stage appears
to be more closely associated with functional status than CD4 or
CD8 lineage. These results may have important implications for
clinical studies of post-SCT immune recovery and GVHD.
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The current study evaluated the clinical efﬁcacy of long-term low
dose acyclovir (ACV) prophylaxis for varicella-zoster virus (VZV)
after allogeneic peripheral blood stem cell transplantation (PB-
SCT). The clinical data of transplant records since 2000 has been
retrospectively retrieved from 2 transplant centers. Princess Mar-
garet Hospital (PMH) group used ACV 400mg/day po till day 28,
whlie Kyungpook National University Hospital (KNUH) group
adopted ACV 800-1200mg/day po till at least 6-9 months. PMH
group (n193) was prone to more lymphoproliferative disorder,
and more TBI-based regimen, while KNUH group (n79) was
prone to more mismatched PBSCT, and high risk acute leukemia
patients. Out of 193 pts in PMH group, 26 patients (13.5%)
received long-term ACV prophylaxis, while 73 patients (92.4%) in
KNUH group received. Overall survival (OS) showed a trend of
favorable survival toward PMH group (p0.227), while no differ-
ence of OS between 2 groups was noted conﬁned to HLA-identical
sibling PBSCT (p0.793). In PMH group, 42 cases (22%) devel-
oped VZV infection presented as localized (n36) or disseminated
involvement (n6), while 6 cases (8%) of VZV infection was noted
in KNUH group presenting as localized involvement (n6;
p0.005). With median 26.5 months of follow-up among survi-
vors, the incidences of VZV infection at 1 and 2 years were
19.23.3 and 27.04.1% in PMH, and 3.42.4 and 8.64.3% in
KNUH group, respectively (p0.002). When conﬁned to HLA-
identical sibling transplants, the incidence of VZV infection at 2
years was 26.44.3% at PMH, and 8.84.4% at KNUH
(p0.004). Taking into account for other potential risk factors for
VZV infection in multivariate analysis, the use of long-term ACV
as a time-dependent covariate was identiﬁed as the only indepen-
dent risk factor for VZV infection after allogeneic PBSCT
(p0.001, HR 0.130, 95% C.I. [0.0400.425]). Long-term use of
ACV seemed to be protective from VZV infection after allogeneic
PBSCT. Further prospective study on the role of low dose ACV is
strongly warranted in allogeneic PBSCT setting.
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The incidence of graft rejection is increasing in association
with an increased use of non-myeloablative conditioning regi-
men, alternative donors, and cord blood transplantation. We
investigated a role of host T cells in graft rejection following
non-myeloablative conditioning bone marrow transplantation
(BMT) in an MHC mismatched B6D2F1 (H-2b/d) into B6
(H-2b) mouse model of BMT, where host T cells can be acti-
vated to kill donor cells. BMT following 6 Gy, 7Gy, and 10Gy
total body irradiation (TBI) resulted in a primary graft rejection,
secondary graft rejection, and engraftment of donor cells, re-
spectively. Interestingly, expansion of host T cells is observed in
the bone marrow and spleen 2 weeks after BMT, followed by a
brisk increase in number of host T cells in peripheral blood one
week later. CD8 T cells isolated from bone marrow produced
interferon-gamma and lysed donor cells. We then examined
whether donor-derived dendritic cells (DCs) play a role in this
rejection, using transgenic mice carrying diphtheria toxin re-
ceptor (DTR) under the control of the CD11c promoter, which
allows selective ablation of CD11c DCs by injection of diph-
theria toxin (DTx), as donors. In the recipients conditioned with
6Gy TBI, depletion of donor-derived DCs with DTx injection
reduced the host T cell-expansion and leads to transient mixed
chimerism in contrast to primary graft rejection in controls. We
then tested whether such an early recovery of host T cells could
be predictive of the graft rejection in 7 adult recipients of
non-myeloablative cord blood transplantation. Three week
post-transplant, an overshoot of host T cells was observed in 2
patients who experienced rejection, but in none of 5 patients
with engraftment. These results suggest that residual host T
cells are associated with graft rejection and an early recovery of
host T cells may be predictive of graft rejection after non-
myloablative allogeneic hematopoietic stem cell transplantation.
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CLINICAL EFFICACY OF CRYOPRESERVED DONOR LYMPHOCYTES FOR
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DLI are frequently employed after nonmyeloablative (mini)
allogeneic marrow transplant (allo-BMT) to enhance chimer-
ism. To ensure the ready availability of cells for DLI we cryo-
preserved CD3 cells from mobilized allo-BMT donors. We
report here the safety and efﬁcacy of infusing cryopreserved
CD3 T cells for DLI (c-DLI) from G-CSF mobilized allo-
PBSC donors and the overall clinical utility of c-DLI. Methods:
Graded doses of CD3 donor T cells from allo-PBSC (2 bags
of 10  106 & 2 of 50  106/kg pt wgt) were cryopreserved in
10% DMSO using a controlled rate freezer and stored in vapor-
phase liquid nitrogen until use. We reviewed patients (pts) who
received allo-BMT for hematologic malignancy from 1/03 to
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12/05 to assess the number of c-DLI administered and the effect
of c-DLI on chimerism. Results: Of 135 allo-BMT, 29 DLI
were administered to 21 pts (median 1 DLI/pt, maximum, 3), 19
of which were c-DLI and 13 of which were for mini-allo-BMT.
A median of 10.5  106 CD3 T cells /kg pt weight (range 5 -
108  106) was administered. No unexpected infusion-related
toxicities or adverse events were encountered. Eight pts were
unevaluable for response, due to full donor chimerism at DLI
(4) or insufﬁcient data after DLI (4). Ten pts received 11 c-DLI
after min-allo-BMT to improve chimerism (4 NHL; 3 CLL; 2
Acute Leukemia; 1 MM). There were 6 responses in T cell
chimerism ( 5% increase) among 5 pts (4 NHL; 1 CLL), 2 to
full donor chimerism (2 NHL). The mean increase in chimerism
after all c-DLIs was 16% (0 - 50) and among responders the
mean increase in T cell chimerism was 24.5% and required a
mean 64 days (range 14 – 130 days). Four of 5 responders were
in CR before c-DLI and remained in CR, while 4 of 5 non-
responders had evidence of disease before and/or after c-DLI
(NS by Chi square). Fifteen pts received 21 c-DLI due to
persistent or recurrent disease (5 AML, 3 CLL, 3 lymphoma, 1
each CML, MM, MDS, Breast). Two pts were not evaluable for
response due to death within 30 days. Three pts had CRs
attributable, at least in part, to DLI (1 each AML, CML, MM).
Conclusions: Prospectively cryopreserved CD3 donor T cells
from mobilized PBSC are frequently employed for DLI after
mini-allo-BMT. Thawed c-DLI are readily available when
needed and are not associated with unexpected infusion toxicity.
C-DLI are frequently effective in improving donor chimerism
post BMT, however a prospective comparison of fresh vs c-DLI
will be required to assess comparative efﬁcacy.
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THYMOGLOBULIN STIMULATES TH2-TYPE ALLORESPONSES AND PRE-
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Thymoglobulin (rabbit anti-thymocyte globulin) is a potent T
cell-depleting agent in-vivo. Nevertheless, its speciﬁc effect on
T cells remains yet to be fully understood. When tested in-vitro
at doses  500 	g/ml thymoglobulin completely depletes T
cells. However, since thymoglobulin level in the serum of
treated patients is consistent with a 100 	g/ml concentration
in-vitro, we tested this dose in culture with puriﬁed T cells
alone, or with allogeneic antigen presenting cells (APCs). Com-
plement and 10% human serum were present in culture media.
In 12-days long kinetics experiments, stimulation with thymo-
globulin on d0, or d0 and d3, or d0, d3 and d6, induced T cell
proliferation, measured by 3H-thymidine uptake, with peaks on
d 4-5. Thymoglobulin also increased T cell responses when
added in primary allogeneic mixed leukocyte culture (MLC). T
cells pretreated with thymoglobulin for 3 d prior to MLC were
hyporesponsive to alloantigen in secondary MLC and did not
show cytotoxic T lymphocyte (CTL) activity, measured by
51Chromium release assay, while proliferated in response to
restimulation with thymoglobulin. Supernatants of MLC with
responder cells pretreated with thymoglobulin for 3 d contained
high levels of IL-13 and IL-5, as opposed to control experiments
with responders pretreated with PHA that showed high levels of
IFN and TNF
. Since after MLC with responders pretreated
with thymoglobulin 90% of T cells were
CD4CD25CD27 we tested the effect of thymoglobulin on
immunomagnetically isolated CD4CD25 (regulatory T
cells, Tregs) or CD4CD25- cells. After 5 d of culture with
thymoglobulin only CD4CD25- cells had proliferated and
both cell subsets expressed CD25, CTLA4, CD62L and GITR.
However, only thymoglobulin-treated CD4CD25 cell ex-
pressed FoxP3 and suppressed T cell alloreactivity when added
to a 3rd party MLC (4227% inhibition). In conclusion, since
we demonstrate that thymoglobulin initially drives T cell allo-
reactivity to Th2-type responses and preserves Tregs immuno-
suppressive activity, these ﬁndings may prompt new studies in
the prevention or treatment of acute GVHD.
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Advances in SCT over the past 2 decades have expanded the
spectrum of PID for which this form of curative therapy has
been utilized. Failed, delayed and loss of donor engraftment and
immune function have emerged as signiﬁcant long-term prob-
lems in children with PID. We report the outcomes of condi-
tioned (COND) and non-conditioned (UNCOND) SCT regi-
mens in PID including: several forms of severe combined
immune deﬁciency (SCID), and non-SCID conditions (Wis-
kott-Aldrich syndrome (WAS), chronic granulomatous disease
(CGD), and Omenn syndrome) over the past 25 years. The
majority of transplants in UNCOND SCID and all UNCOND
non-SCID subjects were performed prior to 1999, utilized T
cell depleted bone marrow from related donors, and did not
include GVHD prophylaxis. The majority of transplants in
COND SCID and all COND non-SCID patients were per-
formed in 1999 or later, utilized bone marrow from matched
unrelated and related donors and CD34 selection of apheresed
mobilized stem cells from mismatched related donors. Prophy-
laxis for GVHD was utilized in all recipients of unselected
marrow and in recipients of CD34 selected stem cell products
with 5  104 T cells/kg. A total of 55 patients received 75
transplants with overall survivals of 64% and 82% in UN-
COND and COND patients respectively. Overall survival in 26
UNCOND SCID patients with related donors was 65% vs 80%
in 10 COND SCID patients. Four of 7 UNCOND non-SCID
patients survived vs. 7 of 8 COND non-SCID patients. Among
SCID survivors, 7, 3, and 1 COND patients and 13, 3, and 1
UNCOND patients received 1, 2, and 3 or more transplants
respectively. Among non-SCID survivors all 4 UNCOND and
6 of 7 COND patients received only 1 transplant. Feeding
problems and failure to thrive occurred frequently in SCID
patients prior to transplantation. Signiﬁcant pre transplant pul-
monary disease adversely affected survival in both COND and
UNCOND patients. Fatal post transplant EBV driven lympho-
proliferation was seen in only 1 patient, following an UN-
COND, T cell depleted bone marrow transplant from a hap-
loidentical, EBV sibling. In COND patients, serious post
transplant infections were related to central venous catheters,
and preexisting pulmonary or GI infection. Our experience
suggests that conditioning for SCID and non-SCID children
with severe PID results in excellent survival and may prove to
offer better long term engraftment and immune recovery.
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NK cells are characterized by absent CD3 and expression of
CD56 and are classiﬁed into CD56dim (90%) that are primarily
cytotoxic, and CD56bright that secrete cytokines (Shankaran et al
Nature 2001). NK subsets carry out their respective functions
based on their repertoire of NK receptors (NKRs) (Moretta et al
Annu Rev Immunol 2001). Despite an immaturity in CB T-cell
immunity, there is a similar leukemic relapse rate following UCBT
vs. UBMT (Cairo et al Blood 1997). Unlike PB NK subsets, there
is little information regarding CB NK subset function and NKR
expression. We compared PB vs. CB NK subset NKR expression
and protein expression. PB and CB cells were positively selected
for CD56 using magnetic beads (Miltenyi) and sorted into CD3
-
/
CD56bright and CD3-/CD56dim and NKR expression measured
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